Skip to content
Research/Metabolic Glp1/Retatrutide

Retatrutide

compound

preliminary evidencePublic

Investigational triple agonist targeting GLP-1R, GIPR, and glucagon receptor. Phase II trials show up to 24% weight loss at 48 weeks — most powerful peptide weight loss to date.

Category: Metabolic Glp1·Updated 5/19/2026
OverviewScienceClinicalSafetyPapersProtocolsOutcomes

Retatrutide

Investigational triple agonist targeting GLP-1R, GIPR, and glucagon receptor. Phase II trials show up to 24% weight loss at 48 weeks — most powerful peptide weight loss to date.

ScienceComing soon
ClinicalComing soon
SafetyComing soon
PapersComing soon
ProtocolsComing soon
OutcomesComing soon